Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration payable	$ 19,833	$ 20,339
Discount rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration payable	19,833	$ 20,339
Callidus Biopharma Inc \| Clinical and regulatory milestones \| ATB200 Pompe Program
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration payable	$ 19,833
Callidus Biopharma Inc \| Clinical and regulatory milestones \| Probability of achievement of milestones \| ATB200 Pompe Program \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, measurement input	80.00%
Callidus Biopharma Inc \| Clinical and regulatory milestones \| Probability of achievement of milestones \| ATB200 Pompe Program \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, measurement input	88.00%
Callidus Biopharma Inc \| Clinical and regulatory milestones \| Discount rate \| Discount rate \| ATB200 Pompe Program \| Probability weighted discounted cash flow
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration, measurement input	8.80%